The use of biosynthetic human growth hormone to augment ovulation induction with buserelin acetate/human menopausal gonadotropin in women with a poor ovarian response**Supported by Nordisk Gentofte A/S, Gentofte, Denmark.††Presented in part at the XIII World Congress of Fertility and Sterility, Marrakesh, Morocco, October 1 to 6, 1989.

1991 ◽  
Vol 55 (1) ◽  
pp. 202-204 ◽  
Author(s):  
Zaky H.Z. Ibrahim ◽  
Phillip L. Matson ◽  
Pamela Buck ◽  
Brian A. Lieberman
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Ovulation Induction ◽  
Human Growth ◽  
Ovarian Response ◽  
Human Menopausal Gonadotropin ◽  
Poor Ovarian Response ◽  
World Congress ◽  
Buserelin Acetate

scholarly journals Human growth hormone use in poor ovarian response – caution and opportunities

2021 ◽  
Vol 15 ◽  
pp. 263349412199942
Author(s):  
Robert J. Norman ◽  
Roger J. Hart
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Live Birth ◽  
Cell Function ◽  
Cumulus Cell ◽  
Human Growth ◽  
Ovarian Response ◽  
Randomised Trials ◽  
Poor Ovarian Response ◽  
Oocyte Maturity

Human growth hormone has found favour as a co-gonadotrophin in assisted reproduction particularly in the circumstances of a poor response to stimulation. Its use has been based on animal studies suggesting insulin-like growth factor-1 enhances granulosa and cumulus cell function and possibly oocyte quality. While there is limited ovarian cellular information in women, the use of human growth hormone is alleged to improve egg numbers, embryo quality, clinical pregnancies and live birth in women with a poor ovarian response. A number of cohort studies have claimed these benefits compared with prior nil treatment, but there are a limited number of quality randomised controlled studies. The few good randomised trials indicate an enhanced ovarian response in terms of oestradiol secretion and oocyte maturity with controversial improvement in ongoing pregnancy and live birth. Given the cost of the medication, the lack of convincing data on enhanced clinical outcomes and the theoretical possibility of side effects, we propose it is still too early to determine human growth hormone’s true cost-benefit for widespread use. However, a number of emerging randomised trials may tilt the equation to a positive outlook in the future. Meanwhile, the hormone should only be used after full informed consent from the patient as to its effectiveness and efficacy.

A new concept of cotreatment with human growth hormone and menotropins in ovulation induction protocols

1997 ◽  
Vol 49 (5) ◽  
pp. 413-415
Author(s):  
R. Orvieto ◽  
R. Homburg ◽  
J. Farhi ◽  
I. Bar-Hava ◽  
Z. Ben-Rafael
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Ovulation Induction ◽  
Human Growth

LIPOLYTIC ACTIVITY OF ENZYME DIGESTED HUMAN GROWTH HORMONE

1965 ◽  
Vol 49 (3_Suppl) ◽  
pp. S143
Author(s):  
Zvi Laron ◽  
Avivah Kowadlo-Silbergeld
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Lipolytic Activity ◽  
Human Growth

The minimal amino acid sequence of the insulin-potentiating fragments of human growth hormone: its mechanism of action

Diabetes ◽  
1980 ◽  
Vol 29 (10) ◽  
pp. 782-787 ◽  
Author(s):  
F. M. Ng ◽  
J. Bornstein ◽  
C. E. Pullin ◽  
J. O. Bromley ◽  
S. L. Macaulay
Keyword(s):  
Growth Hormone ◽  
Amino Acid ◽  
Amino Acid Sequence ◽  
Human Growth Hormone ◽  
Mechanism Of Action ◽  
Human Growth
Sign in / Sign up

Export Citation Format

Share Document